Inactivation of Lrp5 in osteocytes reduces Young's modulus and responsiveness to the mechanical loading

Bone

Volumn 54, Issue 1, 2013, Pages 35-43

  Zhao, Liming ^a   Shim, Joon W ^a   Dodge, Todd R ^a   Robling, Alexander G ^a,b   Yokota, Hiroki ^a,b  

^a Indiana University Purdue University Indianapolis   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lrp5; Mechanotransduction; Osteocytes; Osteoporosis; Young's modulus

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE LENGTH; BONE MASS; BONE MINERAL; BONE STRENGTH; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); FEMUR SHAFT; GENE DELETION; GENE INACTIVATION; LOSS OF FUNCTION MUTATION; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5 GENE; MECHANOTRANSDUCTION; MORPHOMETRICS; MOUSE; MUTATOR GENE; NONHUMAN; OSSIFICATION; OSTEOCYTE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; WEIGHT BEARING; WNT SIGNALING PATHWAY; YOUNG MODULUS;

ALLELES; ANIMALS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE DENSITY; ELASTIC MODULUS; HOMOZYGOTE; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MICE; MICE, KNOCKOUT; ORGAN SIZE; OSTEOCYTES; WEIGHT-BEARING; X-RAY MICROTOMOGRAPHY;

EID: 84873738507     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.01.033     Document Type: Article

References (36)

1. Koay M.A., Brown M.A. Genetic disorders of the LRP5-Wnt signalling pathway affecting the skeleton. Trends Mol Med Mar 2005, 11(3):129-137. [Review].
2. Flaherty M.P., Kamerzell T.J., Dawn B. Wnt signaling and cardiac differentiation. Prog Mol Biol Transl Sci 2012, 111:153-174.
3. Rao T.P., Kühl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res Jun 25 2010, 106(12):1798-1806.
4. Niehrs C., Acebron S.P. Mitotic and mitogenic Wnt signalling. EMBO J May 22 2012, 31(12):2705-2713. 10.1038/emboj.2012.124.
5. Marie P.J. Signaling pathways affecting skeletal health. Curr Osteoporos Rep Sep 2012, 10(3):190-198.
6. Monroe D.G., McGee-Lawrence M.E., Oursler M.J., Westendorf J.J. Update on Wnt signaling in bone cell biology and bone disease. Gene Jan 15 2012, 492(1):1-18. [Epub 2011 Nov 3].
7. Kubota T., Michigami T., Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab 2009, 27(3):265-271. [Epub 2009 Mar 31].
8. He X., Semenov M., Tamai K., Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development Apr 2004, 131(8):1663-1677. [Review].
9. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet Jan 2002, 70(1):11-19. [Epub 2001 Dec 3].
10. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell Nov 16 2001, 107(4):513-523.
11. Hey P.J., Twells R.C., Phillips M.S., Nakagawa Yusuke, Brown S.D., Kawaguchi Y., et al. Cloning of a novel member of the low-density lipoprotein receptor family. Gene Aug 17 1998, 216(1):103-111.
12. Sawakami K., Robling A.G., Ai M., Pitner N.D., Liu D., Warden S.J., et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem Aug 18 2006, 281(33):23698-23711. [Epub 2006 Jun 20].
13. Giangregorio L., Blimkie C.J. Skeletal adaptations to alterations in weight-bearing activity: a comparison of models of disuse osteoporosis. Sports Med 2002, 32(7):459-476.
14. Srinivasan S., Gross T.S., Bain S.D. Bone mechanotransduction may require augmentation in order to strengthen the senescent skeleton. Ageing Res Rev Jul 2012, 11(3):353-360. [Epub 2012 Jan 5].
15. Ozcivici E., Luu Y.K., Adler B., Qin Y.X., Rubin J., Judex S., et al. Mechanical signals as anabolic agents in bone. Nat Rev Rheumatol Jan 2010, 6(1):50-59.
16. Zhang P., Sun Q., Turner C.H., Yokota H. Knee loading accelerates bone healing in mice. J Bone Miner Res Dec 2007, 22(12):1979-1987.
17. Cui Y., Niziolek P.J., MacDonald B.T., Zylstra C.R., Alenina N., Robinson D.R., et al. Lrp5 functions in bone to regulate bone mass. Nat Med Jun 2011, 17(6):684-691. [Epub 2011 May 22].
18. Korvala J., Jüppner H., Mäkitie O., Sochett E., Schnabel D., Mora S., et al. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet Apr 10 2012, 13:26.
19. Lu Y., Xie Y., Zhang S., Dusevich V., Bonewald L.F., Feng J.Q. DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res Apr 2007, 86(4):320-325.
20. Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol Apr 2010, 25(4):603-608. [Epub 2009 Dec 15. Review].
21. Torrance A.G., Mosley J.R., Suswillo R.F., Lanyon L.E. Noninvasive loading of the rat ulna in vivo induces a strain-related modeling response uncomplicated by trauma or periostal pressure. Calcif Tissue Int Mar 1994, 54(3):241-247.
22. Eddleston A., Marenzana M., Moore A.R., Stephens P., Muzylak M., Marshall D., et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res Oct 2009, 24(10):1662-1671.
23. Papapoulos S.E. Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis Mar 2011, 70(Suppl. 1):i119-i122. [Review].
24. Ellies D.L., Viviano B., McCarthy J., Rey J.P., Itasaki N., Saunders S., et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res Nov 2006, 21(11):1738-1749.
25. Balemans W., Piters E., Cleiren E., Ai M., Van Wesenbeeck L., Warman M.L., et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int Jun 2008, 82(6):445-453.
26. van Oers R.F., van Rietbergen B., Ito K., Hilbers P.A., Huiskes R. A sclerostin-based theory for strain-induced bone formation. Biomech Model Mechanobiol Oct 2011, 10(5):663-670. [Epub 2010 Nov 11].
27. Tu X., Rhee Y., Condon K.W., Bivi N., Allen M.R., Dwyer D., et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone Jan 2012, 50(1):209-217. [Epub 2011 Oct 30].
28. Ling Y., Rios H.F., Myers E.R., Lu Y., Feng J.Q., Boskey A.L. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res Dec 2005, 20(12):2169-2177. [Epub 2005 Aug 22].
29. Harris S.E., MacDougall M., Horn D., Woodruff K., Zimmer S.N., Rebel V.I., et al. Meox2Cre-mediated disruption of CSF-1 leads to osteopetrosis and osteocyte defects. Bone Jan 2012, 50(1):42-53. [Epub 2011 Sep 20].
30. Takagi J., Yang Y., Liu J.H., Wang J.H., Springer T.A. Complex between nidogen and laminin fragments reveals a paradigmatic beta-propeller interface. Nature Aug 21 2003, 424(6951):969-974.
31. Yadav V.K., Ryu J.H., Suda N., Tanaka K.F., Gingrich J.A., Schütz G., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell Nov 28 2008, 135(5):825-837.
32. Balemans W., Van Hul W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology Jun 2007, 148(6):2622-2629. [Epub 2007 Mar 29].
33. Baron R., Rawadi G., Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 2006, 76:103-127. [Review].
34. Ono N., Nakashima K., Schipani E., Hayata T., Ezura Y., Soma K., et al. Constitutively active PTH/PTHrP receptor specifically expressed in osteoblasts enhances bone formation induced by bone marrow ablation. J Cell Physiol Feb 2012, 227(2):408-415. 10.1002/jcp. 22986.
35. Zhong Z., Baker J.J., Zylstra-Diegel C.R., Williams B.O. Lrp5 and Lrp6 play compensatory roles in mouse intestinal development. J Cell Biochem Jan 2012, 113(1):31-38. 10.1002/jcb.23324.
36. Hoeppner L.H., Secreto F.J., Westendorf J.J. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets Apr 2009, 13(4):485-496.